These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 6527562)

  • 21. Advances in blood component separation and plasma treatment for therapeutics.
    Malchesky PS; Wojcicki J; Nosé Y
    J Parenter Sci Technol; 1983; 37(1):2-4. PubMed ID: 6834213
    [No Abstract]   [Full Text] [Related]  

  • 22. [Plasmapheresis: methods, indications, practical execution and complications].
    Braun N; Müller GA
    Krankenpfl J; 1994 Sep; 32(9):348-56. PubMed ID: 7933955
    [No Abstract]   [Full Text] [Related]  

  • 23. [Risks and complications of therapeutic plasmapheresis].
    Castelli D
    Ther Umsch; 1982 Jul; 39(7):555-9. PubMed ID: 7123509
    [No Abstract]   [Full Text] [Related]  

  • 24. [Plasmapheresis: technique, complications and indications].
    Pruijm MT; Cherpillod A; Vogt B; Burnier M
    Rev Med Suisse; 2008 Mar; 4(147):581-2, 584-6, 588. PubMed ID: 18402016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Plasmapheresis in medical practice].
    Łapiński TW; Prokopowicz D
    Wiad Lek; 2001; 54(7-8):437-43. PubMed ID: 11641900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous membrane plasma separation: three years of experience.
    Sprenger KB
    Life Support Syst; 1983; 1(4):235-46. PubMed ID: 6679018
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of plasmapheresis in France.
    Cazenave JP; Folléa G
    Hematol Cell Ther; 1996 May; 38 Suppl 1():S25-33. PubMed ID: 8933144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of cellular and plasma apheresis in the critically ill patient: part 1: technical and physiological considerations.
    Linenberger ML; Price TH
    J Intensive Care Med; 2005; 20(1):18-27. PubMed ID: 15665256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasmapheresis in the critically ill patient.
    Berlot G; Tomasini A; Silvestri L; Gullo A
    Kidney Int Suppl; 1998 May; 66():S178-81. PubMed ID: 9573599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Visual evidence of concentration polarization in cross-flow membrane plasmapheresis.
    Ofsthun NJ; Colton CK
    ASAIO Trans; 1987; 33(3):510-7. PubMed ID: 3675981
    [No Abstract]   [Full Text] [Related]  

  • 31. [Plasma exchange therapy (plasmapheresis/plasmafiltration). II. Indications and complications].
    Quietzsch D; Liebert A; Zimmermann S
    Z Gesamte Inn Med; 1984 Oct; 39(20):493-500. PubMed ID: 6549091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic applications of hemapheresis].
    Huestis DW; Pineda AA
    Sangre (Barc); 1982; 27(6):1059-72. PubMed ID: 6764036
    [No Abstract]   [Full Text] [Related]  

  • 33. Hemolysis in membrane plasma separators: is it caused by filter or user?
    Nosé Y
    Artif Organs; 1996 Sep; 20(9):975. PubMed ID: 8864016
    [No Abstract]   [Full Text] [Related]  

  • 34. [Therapeutic apheresis in dermatological disease ].
    Hunziker T
    Ther Umsch; 1982 Jul; 39(7):546-50. PubMed ID: 7123507
    [No Abstract]   [Full Text] [Related]  

  • 35. [An analysis of the complications developing during the performance of plasmapheresis in patients with the late stages of arteriosclerosis obliterans of the vessels of the lower extremities].
    Belotserkovskiĭ MV; Dubikaĭtis AIu; Timofeeva MB; Strashnov VI; Bogomolov MS; Tokarevich KK; Shlomin VV
    Vestn Khir Im I I Grek; 1994; 152(1-2):105-7. PubMed ID: 7701722
    [No Abstract]   [Full Text] [Related]  

  • 36. Efficacy of double-filtration plasmapheretic cross-circulation with a high-permeability membrane using canine harvested liver in porcine fulminant hepatic failure model.
    Ishizawa Y; Totsuka E; Umehara M; Nishimura A; Ono H; Sasaki M
    Transplant Proc; 2004 Oct; 36(8):2344-8. PubMed ID: 15561244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progress in membrane technology and plasmapheresis].
    Ozawa K; Sakai K
    Nihon Rinsho; 1984 Aug; 42(8):1803-9. PubMed ID: 6513050
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapeutic plasmapheresis].
    López Pascual J; Puras Tellaeche A; Montero Castillo J
    Rev Clin Esp; 1983 Sep; 170(6):307-10. PubMed ID: 6658074
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term LDL apheresis does not stably improve hemorheology in hypercholesterolemic patients with coronary artery disease.
    Pusl T; Broedl UC; Parhofer KG; Otto C
    Clin Hemorheol Microcirc; 2009; 41(2):137-42. PubMed ID: 19252236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis.
    Zisimopoulou P; Lagoumintzis G; Kostelidou K; Bitzopoulou K; Kordas G; Trakas N; Poulas K; Tzartos SJ
    J Neuroimmunol; 2008 Sep; 201-202():95-103. PubMed ID: 18667243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.